RE: Italy16 Feb 2021 06:45
Italy
Phase 3 trial of the anti-Covid-19 drug SNG001 in the UNITED States, developed by The British Synairgen
More than a year after the start of the Covid-19 pandemic, we do not yet have a dedicated drug for the treatment and treatment of patients infected with Covid-19. There are, however, several experiments in progress.
In America, phase 3 testing of SNG001, an inhalation drug by The British Synairgen, is kicking off. All the details.
EXPERIMENTATION
Synairgen plc announced that phase 2/3 testing of the inhalation drug SNG001began on Monday, February 15, 2021, as part of the Activ-2 study. Treated patients have mild to moderate symptoms of Sars-Cov-2 that do not yet require hospitalization.
Activ
Activ, the program in which the experimentation of the new hypothetical treatment against Covid has been included, is a public-private partnership born with the aim of developing a coordinated research strategy to accelerate the development of drugs and vaccines against coronavirus.
ACTIV-2 is sponsored bythe National Institute for Allergies and Infectious Diseases (NIAID), the American Institute of Public Health, and is led by the AIDS Clinical Trials Group (ACTG), funded by NIAID.
PHASE 2 STUDIES
The inclusion in the program took place following the results of phase two of the double-blind trial of the drug, concluded on July 20, 2020. The study, called SG016 (EudraCT: 2020-001023-14), involved 221 patients, 101 patients treated in hospital and 120 patients treated at home. The primary endpoint showed that the chances of improvement, across the OSCI scale, for patients who inhaled SNG001 were more than twice as likely as in the placebo group.
THE DRUG
The drug harnesses the power of interferon beta (IFN-beta), a protein found in nature, which orchestrates the body's antiviral responses.
"There is evidence that a shortage of IFN-beta by the lung could explain the increased chance of some patients developing severe lung disease," synairgen explains.
SYNAIRGEN,GEN
Synairgen, a drug research and development company founded by professors stephen Holgate, Donna Davies and Ratko Djukanovic, developed the covid treatment being tested in America.
The company, according to the website,is mainly focused on therapies for the treatment of Covid-19, severe asthma, COPD, and other respiratory diseases. Its main drug is SNG001.
Sign In
Follow the stocks
